Wedad Hanna

Summary

Affiliation: Sunnybrook and Women's College Health Sciences Centre
Country: Canada

Publications

  1. ncbi The role of HER-2/neu oncogene and vimentin filaments in the production of the Paget's phenotype
    Wedad Hanna
    Department of Pathology, Sunnybrook and Women s College Health Sciences Center, Toronto, Ontario, Canada
    Breast J 9:485-90. 2003
  2. ncbi Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm
    Wedad M Hanna
    Department of Anatomic Pathology, Sunnybrook and Women s College Health Sciences Centre, Toronto, ON, Canada
    Mod Pathol 19:481-7. 2006
  3. ncbi Significance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy
    Eileen Rakovitch
    Toronto Sunnybrook Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada
    J Clin Oncol 25:5591-6. 2007
  4. ncbi The management of ductal carcinoma in situ of the breast: a screened population-based analysis
    Eileen Rakovitch
    Department of Radiation Oncology and Health Policy and Evaluation, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont, Canada
    Breast Cancer Res Treat 101:335-47. 2007
  5. ncbi Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event
    Wedad Hanna
    Department of Pathology, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada
    Breast J 13:122-9. 2007
  6. ncbi Mammographic density and the risk of breast cancer recurrence after breast-conserving surgery
    Tulin Cil
    Department of Surgery, University Health Network, and Department of Radiology, Women s College Hospital, Toronto, Ontario, Canada
    Cancer 115:5780-7. 2009
  7. ncbi The role of cytokeratin 5/6 as an adjunct diagnostic tool in breast core needle biopsies
    Sharon Nofech-Mozes
    Department of Pathology, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada
    Int J Surg Pathol 16:399-406. 2008
  8. ncbi Toker cells revisited
    Sharon Nofech-Mozes
    Department of Pathology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
    Breast J 15:394-8. 2009
  9. ncbi Prognostic and predictive molecular markers in DCIS: a review
    Sharon Nofech-Mozes
    Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario, Canada
    Adv Anat Pathol 12:256-64. 2005
  10. ncbi Is expert breast pathology assessment necessary for the management of ductal carcinoma in situ ?
    Eileen Rakovitch
    Department of Radiation Oncology, Toronto Sunnybrook Regional Cancer Centre, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue, Ontario, Canada
    Breast Cancer Res Treat 87:265-72. 2004

Detail Information

Publications27

  1. ncbi The role of HER-2/neu oncogene and vimentin filaments in the production of the Paget's phenotype
    Wedad Hanna
    Department of Pathology, Sunnybrook and Women s College Health Sciences Center, Toronto, Ontario, Canada
    Breast J 9:485-90. 2003
    ....
  2. ncbi Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm
    Wedad M Hanna
    Department of Anatomic Pathology, Sunnybrook and Women s College Health Sciences Centre, Toronto, ON, Canada
    Mod Pathol 19:481-7. 2006
    ..The high level of concordance between FISH and CISH seen in this study suggests that CISH may be a viable alternative to FISH for use in the human epidermal growth factor receptor-2 testing algorithm...
  3. ncbi Significance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy
    Eileen Rakovitch
    Toronto Sunnybrook Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada
    J Clin Oncol 25:5591-6. 2007
    ..The objective of this study is to evaluate the significance of multifocality and the outcomes of women with multifocal DCIS treated with breast-conserving therapy...
  4. ncbi The management of ductal carcinoma in situ of the breast: a screened population-based analysis
    Eileen Rakovitch
    Department of Radiation Oncology and Health Policy and Evaluation, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ont, Canada
    Breast Cancer Res Treat 101:335-47. 2007
    ..We report a patterns of care study of women with DCIS to better understand the gap between evidence-based knowledge and the management of DCIS...
  5. ncbi Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event
    Wedad Hanna
    Department of Pathology, Sunnybrook Health Sciences Center, Toronto, Ontario, Canada
    Breast J 13:122-9. 2007
    ....
  6. ncbi Mammographic density and the risk of breast cancer recurrence after breast-conserving surgery
    Tulin Cil
    Department of Surgery, University Health Network, and Department of Radiology, Women s College Hospital, Toronto, Ontario, Canada
    Cancer 115:5780-7. 2009
    ..To the authors' knowledge, the role of mammographic density as a risk factor for the development of local recurrence has not been thoroughly evaluated to date...
  7. ncbi The role of cytokeratin 5/6 as an adjunct diagnostic tool in breast core needle biopsies
    Sharon Nofech-Mozes
    Department of Pathology, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada
    Int J Surg Pathol 16:399-406. 2008
    ..Cytokeratin 5/6 can be a useful adjunct in cases with ductal hyperplasia but not in columnar cell lesions, where it is universally negative...
  8. ncbi Toker cells revisited
    Sharon Nofech-Mozes
    Department of Pathology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
    Breast J 15:394-8. 2009
    ..The substantial number and the clustering of Toker cells should not be mistaken for PD of the nipple. Unlike PD, Toker cells have small bland nuclei and are characterized by CK7+ and HER2/neu ER and PR negative immunoprofile...
  9. ncbi Prognostic and predictive molecular markers in DCIS: a review
    Sharon Nofech-Mozes
    Department of Pathology, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario, Canada
    Adv Anat Pathol 12:256-64. 2005
    ..However, controversies exist regarding the value of these prognostic factors, their interrelationship, and their advantages over morphologic evaluation...
  10. ncbi Is expert breast pathology assessment necessary for the management of ductal carcinoma in situ ?
    Eileen Rakovitch
    Department of Radiation Oncology, Toronto Sunnybrook Regional Cancer Centre, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue, Ontario, Canada
    Breast Cancer Res Treat 87:265-72. 2004
    ..The objective of this study was to evaluate the completeness and accuracy of pathologic reporting of DCIS over the past decade and to determine the current impact of expert breast pathology assessment on the management of DCIS...
  11. ncbi Cutaneous myoepithelioma arising within hidradenoma of the scalp
    Kiran Jakate
    Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
    J Cutan Pathol 39:279-85. 2012
    ..In addition to discussing this case, we provide a brief review of epithelial-myoepithelial neoplasms encountered in the skin...
  12. ncbi The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer
    Laszlo Radvanyi
    Sanofi Pasteur, Toronto, Ontario, Canada M2R 3T4
    Proc Natl Acad Sci U S A 102:11005-10. 2005
    ..1 transgenic mouse. Human T cell lines from HLA-A*0201+ female donors exhibiting TRPS-1-specific cytotoxic T lymphocyte activity could also be generated...
  13. ncbi KIT gene mutations and patterns of protein expression in mucosal and acral melanoma
    Suzan Abu-Abed
    Department of Anatomical Pathology, Sunnybrook Health Sciences Centre, Toronto, ON
    J Cutan Med Surg 16:135-42. 2012
    ..In particular, certain subtypes harbor mutations similar to those observed in gastrointestinal stromal tumors, which are sensitive to treatment with tyrosine kinase inhibitors...
  14. ncbi Expression of TdT in Merkel cell carcinoma and small cell lung carcinoma
    Michael Sidiropoulos
    Dept of Pathology, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave, Toronto, Ontario, Canada
    Am J Clin Pathol 135:831-8. 2011
    ..TdT may be beneficial in rare cases of CK20- MCC and may assist in distinguishing between MCC and SCLC. There is significant immunohistochemical variability and overlap between these 2 tumors...
  15. ncbi Aggressive giant fibroepithelial lesion with unusual vascular stroma--a case report
    Wedad Hanna
    Department of Anatomical Pathology, Sunnybrook and Women s College Health Science Center, University of Toronto, Ontario, Canada
    Mod Pathol 16:823-7. 2003
    ..The extensive vascular stroma noted in the primary tumor may have played a role in the malignant transformation of the epithelial and stromal components in this tumor...
  16. ncbi Prognostic factors affecting the natural history of node-negative breast cancer
    Maureen E Trudeau
    Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
    Breast Cancer Res Treat 89:35-45. 2005
    ..We undertook a natural history investigation of a broad selection of prognostic factors in a cohort of women with node-negative breast cancer...
  17. ncbi A novel RING-type ubiquitin ligase breast cancer-associated gene 2 correlates with outcome in invasive breast cancer
    Angelika M Burger
    Laboratories of Molecular Pathology, Department of Anatomic Pathology, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Cancer Res 65:10401-12. 2005
    ..Its association with clinical measures and its effects on cell growth indicate that BCA2 may be important for the ubiquitin modification of proteins crucial to breast carcinogenesis and growth...
  18. ncbi Re: High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system
    Wedad M Hanna
    Mod Pathol 21:1278-80; author reply 1280-1. 2008
  19. ncbi American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
    Antonio C Wolff
    American Society of Clinical Oncology, Alexandria, VA, USA
    J Clin Oncol 25:118-45. 2007
    ..To develop a guideline to improve the accuracy of human epidermal growth factor receptor 2 (HER2) testing in invasive breast cancer and its utility as a predictive marker...
  20. ncbi Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis
    Judith Anne W Chapman
    Department of Public Health Sciences, Faculty of Medicine, University of Toronto, and Department of Laboratory Medicine and Pathology, St Michael s Hospital, Toronto, Ontario, Canada
    Breast J 12:37-47. 2006
    ..Estimated prognoses may differ substantially by survival analysis model type, by amounts that might affect patient management, and we think that the log-normal model has a major advantage over the Cox model for survival analysis...
  21. ncbi Biological significance of occult micrometastases in histologically negative axillary lymph nodes in breast cancer patients using the recent American Joint Committee on Cancer breast cancer staging system
    Harriette J Kahn
    Department of Pathology, Sunnybrook and Women s College Health Sciences Center, Toronto, Ontario, Canada
    Breast J 12:294-301. 2006
    ..This information is important with regard to the practice of sentinel node biopsy and subsequent axillary node dissection and to the decision to administer adjuvant therapy based on detection of micrometastases in lymph nodes...
  22. ncbi Standardization of HER2 testing: results of an international proficiency-testing ring study
    Mitch Dowsett
    Academic Depertment of Biochemistry, Royal Marsden Hospital, London, UK
    Mod Pathol 20:584-91. 2007
    ..7-2.3 by at least one center. Equivocal immunohistochemistry and borderline FISH cases are difficult to interpret, even for highly experienced and validated laboratories, highlighting the need for quality-control procedures...
  23. ncbi Expression of c-kit in fibroepithelial lesions of the breast is a mast cell phenomenon
    Bojana Djordjevic
    Department of Pathology, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, ON, Canada
    Mod Pathol 21:1238-45. 2008
    ..C-kit, therefore, has neither a diagnostic nor a prognostic role in phyllodes tumors, and there is no rationale for the treatment of recurrent of malignant phyllodes tumor patients with tyrosine kinase inhibitors...
  24. ncbi Triple-negative breast cancer: clinical features and patterns of recurrence
    Rebecca Dent
    Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
    Clin Cancer Res 13:4429-34. 2007
    ..To compare the clinical features, natural history, and outcomes for women with "triple-negative" breast cancer with women with other types of breast cancer...
  25. ncbi Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type
    William D Foulkes
    Departments of Oncology, Sir M B Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Clin Cancer Res 10:2029-34. 2004
    ..The relationship between ER status and other clinical features of hereditary breast cancers has not been well studied...
  26. ncbi The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer
    Shelley B Bull
    Fred A. Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario M5G 1X5, Canada
    J Clin Oncol 22:86-96. 2004
    ....
  27. ncbi Immunophenotyping of serous carcinoma of the female genital tract
    Sharon Nofech-Mozes
    Department of Anatomic Pathology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
    Mod Pathol 21:1147-55. 2008
    ..HER2/neu was exclusively overexpressed in serous carcinomas of endometrial origin...